Summary
Medtronic plc reported strong financial results for the six months ended October 29, 2021, with net sales increasing by 12% to $15.8 billion and net income attributable to Medtronic more than doubling to $2.1 billion compared to the same period last year. This growth was driven by a recovery in global procedural volumes following the COVID-19 pandemic, particularly in international markets, and solid performance across its Cardiovascular, Medical Surgical, and Neuroscience segments. The company also demonstrated robust operating cash flow, generating $3.1 billion for the six-month period, and a free cash flow of $2.4 billion, underscoring its financial strength and ability to fund operations and return value to shareholders. The company's strategic focus on innovation and market expansion continues to yield positive results, with key product launches and advancements contributing to segment growth. Despite ongoing challenges related to COVID-19, including supply constraints and healthcare system staffing shortages impacting the U.S. market, Medtronic's diversified portfolio and global presence have enabled it to navigate these headwinds. The company's strong balance sheet and liquidity position provide confidence in its ability to manage foreseeable operating needs and pursue strategic capital allocation alternatives.
Financial Highlights
54 data points| Revenue | $7.85B |
| Cost of Revenue | $2.50B |
| Gross Profit | $5.35B |
| SG&A Expenses | $2.62B |
| Operating Income | $1.56B |
| Interest Expense | $136.00M |
| Net Income | $1.31B |
| EPS (Basic) | $0.97 |
| EPS (Diluted) | $0.97 |
| Shares Outstanding (Basic) | 1.35B |
| Shares Outstanding (Diluted) | 1.36B |
Key Highlights
- 1Net sales increased 12% to $15.8 billion for the six months ended October 29, 2021, compared to $14.1 billion in the prior year.
- 2Net income attributable to Medtronic significantly increased to $2.07 billion for the six months ended October 29, 2021, up from $976 million in the prior year.
- 3Diluted earnings per share were $1.53 for the six months ended October 29, 2021, a substantial increase from $0.72 in the prior year.
- 4Operating cash flow for the six months ended October 29, 2021, was $3.06 billion, a notable increase from $2.14 billion in the prior year.
- 5Free cash flow for the six months ended October 29, 2021, was $2.41 billion, up from $1.52 billion in the prior year.
- 6The Cardiovascular segment showed strong growth, with net sales up 11% to $5.7 billion for the six months ended October 29, 2021.
- 7The company announced a pending acquisition of Intersect ENT for approximately $1.1 billion, expected to close by the end of fiscal year 2022.